Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2025-12-03 00:00:00 ET · period of report 2025-12-01 · accession 0000882796-25-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-03 | 2025-12-01 | BCRX | Barnes Alane P | CLO | M - OptEx | $3.22 | +91.0K | 507.2K | +22% | +$293.0K |
| DM | 2025-12-03 | 2025-12-01+ | BCRX | Barnes Alane P | CLO | S - Sale+OE | $7.20 | -161.7K | 345.5K | -32% | -$1.16M |
| D | 2025-12-03 | 2025-12-01 | BCRX | Barnes Alane P | CLO | M - OptEx | $0.00 | -91.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-01 | M | A | 91,004 | $3.22 | 507,156 | D | — | — | (F1) This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
| 2 | Common | Common Stock | 2025-12-01 | S | D | 91,004 | $7.10 | 416,152 | D | — | — | (F1) This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. (F2) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.015 to $7.190. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-12-02 | S | D | 50,906 | $7.21 | 365,246 | D | — | — | (F3) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.180 to $7.255. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2025-12-03 | S | D | 19,770 | $7.65 | 345,476 | D | — | — | (F1) This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
| 5 | Derivative | Emp. Stock Option (Right to Buy) | 2025-12-01 | M | D | 91,004 | $0.00 | 0 | D | $3.22 · 2017-05-23 to 2026-05-23 | 91,004 Common Stock | (F1) This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. (F4) The option grant became exercisable at the rate of 25.0% on each of the first, second, third, and fourth anniversaries of the date of grant. |